Pietro Fagiolino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/840313/publications.pdf Version: 2024-02-01



PIETRO FACIOLINO

#	Article	IF	CITATIONS
1	Hyperammonemia Associated with Valproic Acid Concentrations. BioMed Research International, 2014, 2014, 1-7.	0.9	41
2	Influence of Efflux Transporters on Drug Metabolism. Clinical Pharmacokinetics, 2011, 50, 75-80.	1.6	32
3	Carnitine and/or Acetylcarnitine Deficiency as a Cause of Higher Levels of Ammonia. BioMed Research International, 2016, 2016, 1-8.	0.9	32
4	The Influence of Cardiovascular Physiology on Dose/Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Relationships. Clinical Pharmacokinetics, 2006, 45, 433-448.	1.6	29
5	Chronic administration of phenytoin induces efflux transporter overexpression in rats. Pharmacological Reports, 2014, 66, 946-951.	1.5	28
6	Potential Therapeutic Role of Carnitine and Acetylcarnitine in Neurological Disorders. Current Pharmaceutical Design, 2020, 26, 1277-1285.	0.9	28
7	Sex Effect on Average Bioequivalence. Clinical Therapeutics, 2017, 39, 23-33.	1.1	27
8	L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report. Journal of International Medical Research, 2017, 45, 1268-1272.	0.4	22
9	Evaluation of pharmacological interactions after administration of a levamisole, albendazole and ivermectin triple combination in lambs. Veterinary Parasitology, 2014, 201, 110-119.	0.7	18
10	Population Pharmacokinetics of Clozapine and Norclozapine and Switchability Assessment between Brands in Uruguayan Patients with Schizophrenia. BioMed Research International, 2019, 2019, 1-10.	0.9	18
11	Stereoselective Pharmacokinetics of Ketoprofen After Oral Administration of Modified-Release Formulations in Caucasian Healthy Subjects. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 787-793.	0.6	17
12	The influence of cardiac output distribution on the tissue/plasma drug concentration ratio. European Journal of Drug Metabolism and Pharmacokinetics, 2002, 27, 79-81.	0.6	16
13	Integration of in vitro biorelevant dissolution and in silico PBPK model of carvedilol to predict bioequivalence of oral drug products. European Journal of Pharmaceutical Sciences, 2018, 118, 176-182.	1.9	16
14	Population pharmacokinetic model to analyze nevirapine multiple-peaks profile after a single oral dose. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 363-373.	0.8	14
15	Multiplicative dependence of the first order rate constant and its impact on clinical pharmacokinetics and bioequivalence. European Journal of Drug Metabolism and Pharmacokinetics, 2004, 29, 43-49.	0.6	13
16	Sex and Food Influence on Intestinal Absorption of Ketoprofen Gastroresistant Formulation. Clinical Pharmacology in Drug Development, 2016, 5, 196-200.	0.8	13
17	Sex-by-formulation interaction assessed through a bioequivalence study of efavirenz tablets. European Journal of Pharmaceutical Sciences, 2016, 85, 106-111.	1.9	13
18	Lamotrigine-Valproic Acid Interaction Leading to Stevens–Johnson Syndrome. Case Reports in Medicine, 2018, 2018, 1-5.	0.3	13

PIETRO FAGIOLINO

#	Article	IF	CITATIONS
19	Enteric reabsorption processes and their impact on drug pharmacokinetics. Scientific Reports, 2021, 11, 5794.	1.6	13
20	Verapamil effect on phenytoin pharmacokinetics in rats. Epilepsy Research, 2013, 107, 51-55.	0.8	12
21	Systemic and presystemic conversion of carbamazepine to carbamazepine-10,11-epoxide during long term treatment. Journal of Epilepsy and Clinical Neurophysiology, 2006, 12, 13-16.	0.1	12
22	Pharmacokinetics of Subcutaneous Levetiracetam in Palliative Care Patients. Journal of Palliative Medicine, 2021, 24, 248-251.	0.6	11
23	Therapeutic carbamazepine (CBZ) and valproic acid (VPA) monitoring in children using saliva as a biologic fluid. Journal of Epilepsy and Clinical Neurophysiology, 2008, 14, 55-58.	0.1	10
24	Concentration-Dependent Mechanisms of Adverse Drug Reactions in Epilepsy. Current Pharmaceutical Design, 2013, 19, 6802-6808.	0.9	10
25	The role of efflux transporters and metabolizing enzymes in brain and peripheral organs to explain drugâ€resistant epilepsy. Epilepsia Open, 2022, 7, .	1.3	9
26	Contribution of the Antiepileptic Drug Administration Regime in the Development and/or Establishment of Pharmacoresistant Epilepsy. , 2013, , 169-184.		9
27	Usefulness of Salivary Drug Monitoring for Detecting Efflux Transporter Overexpression. Current Pharmaceutical Design, 2013, 19, 6701-6708.	0.9	9
28	Clinical Pharmacokinetics of Cannabinoids and Potential Drug-Drug Interactions. Advances in Experimental Medicine and Biology, 2021, 1297, 27-42.	0.8	8
29	Itraconazole Bioequivalence Revisited: Influence of Gender on Highly Variable Drugs. The Open Drug Metabolism Journal, 2007, 1, 7-13.	0.5	8
30	Sex- and smoke-related differences in gastrointestinal transit of cyclosporin A microemulsion capsules. European Journal of Pharmaceutical Sciences, 2014, 63, 140-146.	1.9	7
31	Clearance and bioavailability study through arterio-venous drug concentrations relationship. European Journal of Pharmaceutical Sciences, 2013, 48, 825-829.	1.9	6
32	Development of a Population Pharmacokinetic Model for Cyclosporine from Therapeutic Drug Monitoring Data. BioMed Research International, 2021, 2021, 1-9.	0.9	6
33	Antiepileptic drugs: Energy-consuming processes governing drug disposition. Frontiers in Bioscience - Elite, 2014, E6, 387.	0.9	6
34	ls saliva suitable as a biological fluid in relative bioavailability studies? Analysis of its performance in a 4Â×Â2 replicate crossover design. European Journal of Drug Metabolism and Pharmacokinetics, 2011, 36, 229-236.	0.6	5
35	Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects. Pharmaceuticals, 2017, 10, 73.	1.7	5
36	Antiepileptic drugs Energy-consuming processes governing drug disposition. Frontiers in Bioscience - Elite, 2014, 6, 387-396.	0.9	3

PIETRO FAGIOLINO

#	Article	IF	CITATIONS
37	Drug-Drug and Food-Drug Interactions of Pharmacokinetic Nature. , 2018, , 271-299.		3
38	Sexâ€byâ€formulation interaction in bioequivalence studies: the importance of formulations and experimental conditions. British Journal of Clinical Pharmacology, 2019, 85, 669-671.	1.1	3
39	Current PBPK Models: Are They Predicting Tissue Drug Concentration Correctly?. Drugs in R and D, 2020, 20, 295-299.	1.1	3
40	Sex-related in vitro/in vivo and PK/PD correlations after oral single dose furosemide administration. Journal of Pharmaceutical Technology & Drug Research, 2016, 5, 2.	1.0	3
41	Tissue Drug Concentration. Current Pharmaceutical Design, 2022, 28, 1109-1123.	0.9	3
42	Active Pharmacovigilance in Epileptic Patients: A Deep Insight into Phenytoin Behaviour. , 2019, , .		2
43	Impact of Severe Sepsis or Septic Shock on Drug Response. , 2012, , .		1
44	Complete dataset for 2-treatment, 2-sequence, 2-period efavirenz bioequivalence study conducted with nightly dosing. Data in Brief, 2016, 7, 751-754.	0.5	1
45	Pharmacotherapy of Chronic Pain. , 0, , .		1
46	Correlation of methadone concentrations in plasma and saliva collected with and without stimulation in pain management patients. Clinical Chemistry and Laboratory Medicine, 2015, 53, e109-12.	1.4	0
47	Therapeutic Monitoring of Anticonvulsants: Use of Saliva as Biological Fluid. , 0, , .		Ο
48	Influence of Sex and Food on the Bioavailability and the R-to-S Conversion of Ketoprofen Stereoisomers in Humans. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 167-169.	0.6	0
49	Nonlinear Pharmacokinetics: Negative Deviation from Linearity. , 2021, , 1-6.		Ο
50	Concentration-Dependent Nonlinear Pharmacokinetics. , 2021, , 1-7.		0
51	Cyclical Variation of Linear and Nonlinear Pharmacokinetic Responses. , 2021, , 1-10.		0
52	Cyclical Variation of Linear and Nonlinear Pharmacokinetic Responses. , 2022, , 281-289.		0
53	Concentration-Dependent Nonlinear Pharmacokinetics. , 2022, , 274-280.		0
54	Time-Dependent Nonlinear Pharmacokinetics. , 2022, , 1121-1128.		0

4

#	Article	IF	CITATIONS
55	Nonlinear Pharmacokinetics: Negative Deviation from Linearity. , 2022, , 689-694.		0
56	Nonlinear Pharmacokinetic Responses in Variant Systems. , 2022, , 683-689.		0
57	Nonlinear Pharmacokinetics: Positive Deviation from Linearity. , 2022, , 694-698.		0